PL314003A1 - Combination of bisulphonates and substances enhancing secretion of growth hormone - Google Patents

Combination of bisulphonates and substances enhancing secretion of growth hormone

Info

Publication number
PL314003A1
PL314003A1 PL94314003A PL31400394A PL314003A1 PL 314003 A1 PL314003 A1 PL 314003A1 PL 94314003 A PL94314003 A PL 94314003A PL 31400394 A PL31400394 A PL 31400394A PL 314003 A1 PL314003 A1 PL 314003A1
Authority
PL
Poland
Prior art keywords
bisulphonates
combination
growth hormone
enhancing secretion
substances enhancing
Prior art date
Application number
PL94314003A
Inventor
Barry J Gertz
Gideon A Rodan
Roy G Smith
Matthew J Wyvratt
Arthur A Patchett
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PL314003A1 publication Critical patent/PL314003A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL94314003A 1993-10-19 1994-10-18 Combination of bisulphonates and substances enhancing secretion of growth hormone PL314003A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13929693A 1993-10-19 1993-10-19
US25909194A 1994-06-13 1994-06-13

Publications (1)

Publication Number Publication Date
PL314003A1 true PL314003A1 (en) 1996-08-05

Family

ID=26837073

Family Applications (1)

Application Number Title Priority Date Filing Date
PL94314003A PL314003A1 (en) 1993-10-19 1994-10-18 Combination of bisulphonates and substances enhancing secretion of growth hormone

Country Status (16)

Country Link
EP (1) EP0813414A4 (en)
JP (1) JPH09504525A (en)
KR (1) KR960705575A (en)
CN (1) CN1136278A (en)
AU (1) AU8083694A (en)
BG (1) BG100517A (en)
BR (1) BR9407869A (en)
CA (1) CA2173333A1 (en)
CZ (1) CZ109196A3 (en)
FI (1) FI961681A (en)
HU (1) HUT75224A (en)
LV (1) LV11432B (en)
NO (1) NO961536L (en)
PL (1) PL314003A1 (en)
SK (1) SK49796A3 (en)
WO (1) WO1995011029A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
DE69533991T2 (en) * 1995-05-29 2006-04-13 Pfizer Inc. DIPEPTIDES THAT STIMULATE THE DISTRIBUTION OF GROWTH HORMONES
JPH11513989A (en) * 1995-10-27 1999-11-30 メルク エンド カンパニー インコーポレーテッド Wet granulation of growth hormone secretagogue
WO1997022004A1 (en) 1995-12-13 1997-06-19 Merck & Co., Inc. Assays for growth hormone secretagogue receptors
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS
AU3025997A (en) * 1996-05-31 1998-01-05 Novo Nordisk A/S Growth hormone component and bone anti-resorptive agent in cyclic (coherence) treatment of osteoporosis
WO1998018815A1 (en) * 1996-10-25 1998-05-07 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
IT1296495B1 (en) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa USE OF BISPHOSPHONATES IN THE PREPARATION OF PHARMACEUTICAL FORMS FOR INTRAMUSCULAR ADMINISTRATION
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
EP1097170A1 (en) 1998-07-13 2001-05-09 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
WO2000009538A2 (en) 1998-08-10 2000-02-24 Merck & Co., Inc. Canine growth hormone secretagogue receptor
WO2000010565A1 (en) * 1998-08-18 2000-03-02 Eli Lilly And Company Growth hormone secretagogues
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
AR013994A1 (en) * 1998-10-30 2001-01-31 Gador Sa PROCEDURE AND PREPARATIONS THAT SELECTIVELY MODULATE THE FUNCTION OF THE OSTEOBLASTO FOR THE PREVENTION AND TREATMENT OF FRAGILIZING OSTEOPATHIES.
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
EP1188441A4 (en) * 1999-06-02 2004-01-28 Procter & Gamble Oral preparations of etidronate disodium
EP1159964B1 (en) 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
US6548042B2 (en) 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
ES2243457T3 (en) * 2001-01-23 2005-12-01 Gador S.A. COMPOSITION THAT INCLUDES BIFOSPHONATES FOR THE PREVENTION AND / OR TREATMENT OF METABOLIC BONE DISORDERS, PROCEDURE OF PREPARATION OF SUCH COMPOSITION AND USES OF THE SAME.
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
US7396846B2 (en) 2002-04-09 2008-07-08 Eli Lilly And Company Growth hormone secretagogues
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
AU2004237438B2 (en) * 2003-05-07 2011-01-20 Osteologix A/S Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
NZ553202A (en) 2004-08-19 2010-12-24 Vertex Pharma Modulators of muscarinic receptors
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
AU2005309365B2 (en) 2004-11-29 2011-10-06 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2006330866A1 (en) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
NZ570497A (en) 2006-02-22 2011-09-30 Vertex Pharma Spiro condensed 4,4'-quinilino-piperidines derivatives as modulators of muscarinic receptors
KR20080094964A (en) 2006-02-22 2008-10-27 버텍스 파마슈티칼스 인코포레이티드 Modulators of muscarinic receptors
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
US7858790B2 (en) 2006-06-29 2010-12-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008021375A2 (en) 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008021545A2 (en) 2006-08-18 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
EA200901077A1 (en) 2007-02-09 2010-04-30 Транзим Фарма, Инк. MACRO CYCLIC MODULATORS OF THE GREEL RECEPTOR AND THEIR APPLICATION
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
EP2207549A1 (en) 2007-10-03 2010-07-21 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
KR20160147007A (en) 2014-05-30 2016-12-21 화이자 인코포레이티드 Carbonitrile derivatives as selective androgen receptor modulators
MX2020013236A (en) 2018-06-06 2021-02-22 Massachusetts Inst Technology Circular rna for translation in eukaryotic cells.
IL310266A (en) 2019-05-22 2024-03-01 Massachusetts Inst Technology Circular rna compositions and methods
JP2023504568A (en) 2019-12-04 2023-02-03 オルナ セラピューティクス インコーポレイテッド Circular RNA compositions and methods
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU568433B2 (en) * 1984-04-30 1987-12-24 Procter & Gamble Company, The Treating osteoporosis
AU569391B2 (en) * 1984-04-30 1988-01-28 Procter & Gamble Company, The Treating osteoporosis
RO115804B1 (en) * 1992-12-11 2000-06-30 Merck & Co Inc Spiropyperidine derivatives, processes for preparation and pharmaceutical compositions thereof
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) * 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5545735A (en) * 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone

Also Published As

Publication number Publication date
BG100517A (en) 1996-11-29
NO961536D0 (en) 1996-04-18
FI961681A (en) 1996-06-12
JPH09504525A (en) 1997-05-06
CA2173333A1 (en) 1995-04-27
KR960705575A (en) 1996-11-08
HUT75224A (en) 1997-04-28
EP0813414A4 (en) 1999-07-21
LV11432B (en) 1996-12-20
FI961681A0 (en) 1996-04-17
CN1136278A (en) 1996-11-20
LV11432A (en) 1996-08-20
BR9407869A (en) 1996-10-29
EP0813414A1 (en) 1997-12-29
NO961536L (en) 1996-06-18
HU9601013D0 (en) 1996-06-28
CZ109196A3 (en) 1996-10-16
WO1995011029A1 (en) 1995-04-27
SK49796A3 (en) 1997-05-07
AU8083694A (en) 1995-05-08

Similar Documents

Publication Publication Date Title
PL314003A1 (en) Combination of bisulphonates and substances enhancing secretion of growth hormone
AU4156693A (en) Variants of parathyroid hormone and its fragments
IL104007A0 (en) Adhesive composition and method of using it
EP0741578A4 (en) Human growth hormone
IL128128A (en) Composition comprising insulin and insulin-like growth factor (i-igf)
GB9322628D0 (en) Microencapsualted adhesive composition and method of making same
GB9121289D0 (en) Composition and use
IL108142A0 (en) Aminoureaformaldehyde fertilizer composition and its preparation
GB9013410D0 (en) Polypeptide and its use
EP0726901A4 (en) Benzo-fused macrocycles promote release of growth hormone
AU2525092A (en) Combination containing growth factors and polyelectrolytes
EP0445801A3 (en) Peptide and its use
IL101587A0 (en) Biologically active peptide composition and uses therefor
HU9402361D0 (en) New makrolides and use of them
ZA897446B (en) Antimicrobial composition and method of use
ZA93582B (en) Substituted hexahyhdroazephinones and tetrahydrobenzazepinones
GB9103631D0 (en) Composition and use
GB2279956B (en) Recombinant human and rat AMP-protein kinases
GB9224295D0 (en) Method and composition
GB9216776D0 (en) Composition and use
NZ268125A (en) Growth hormone pharmaceutical composition
AU8603591A (en) Peptide and its use
GB9318480D0 (en) Briquette and preparation of same
GB9306456D0 (en) Composition and use
SI0935469T1 (en) Use of growth hormone